Literature DB >> 18339321

MeCP2 preferentially binds to methylated linker DNA in the absence of the terminal tail of histone H3 and independently of histone acetylation.

Toyotaka Ishibashi1, Anita A Thambirajah, Juan Ausió.   

Abstract

Methyl CpG binding protein 2 (MeCP2) is a basic protein that contains a DNA methyl binding domain. The mechanism by which the highly positive charge of MeCP2 and its ability to bind methylated DNA contribute to the specificity of its binding to chromatin has long remained elusive. In this paper, we show that MeCP2 binds to nucleosomes in a very similar way to linker histones both in vitro and in vivo. However, its binding specificity strongly depends on DNA methylation. We also observed that as with linker histones, this binding is independent of the core histone H3 N-terminal tail and is not affected by histone acetylation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18339321     DOI: 10.1016/j.febslet.2008.03.005

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  21 in total

1.  MeCP2 is required for global heterochromatic and nucleolar changes during activity-dependent neuronal maturation.

Authors:  Malaika K Singleton; Michael L Gonzales; Karen N Leung; Dag H Yasui; Diane I Schroeder; Keith Dunaway; Janine M LaSalle
Journal:  Neurobiol Dis       Date:  2011-03-21       Impact factor: 5.996

Review 2.  Binding of the Rett syndrome protein, MeCP2, to methylated and unmethylated DNA and chromatin.

Authors:  Jeffrey C Hansen; Rajarshi P Ghosh; Christopher L Woodcock
Journal:  IUBMB Life       Date:  2010-10       Impact factor: 3.885

Review 3.  Genetic syndromes caused by mutations in epigenetic genes.

Authors:  María Berdasco; Manel Esteller
Journal:  Hum Genet       Date:  2013-01-31       Impact factor: 4.132

4.  The characterization of macroH2A beyond vertebrates supports an ancestral origin and conserved role for histone variants in chromatin.

Authors:  Ciro Rivera-Casas; Rodrigo Gonzalez-Romero; Manjinder S Cheema; Juan Ausió; José M Eirín-López
Journal:  Epigenetics       Date:  2016-04-15       Impact factor: 4.528

5.  Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state.

Authors:  Peter J Skene; Robert S Illingworth; Shaun Webb; Alastair R W Kerr; Keith D James; Daniel J Turner; Rob Andrews; Adrian P Bird
Journal:  Mol Cell       Date:  2010-02-26       Impact factor: 17.970

6.  Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity.

Authors:  Katrina V Good; Alexia Martínez de Paz; Monica Tyagi; Manjinder S Cheema; Anita A Thambirajah; Taylor L Gretzinger; Gilda Stefanelli; Robert L Chow; Oliver Krupke; Michael Hendzel; Kristal Missiaen; Alan Underhill; Nicoletta Landsberger; Juan Ausió
Journal:  Epigenetics       Date:  2017-12-05       Impact factor: 4.528

Review 7.  Recent advances in MeCP2 structure and function.

Authors:  Kristopher C Hite; Valerie H Adams; Jeffrey C Hansen
Journal:  Biochem Cell Biol       Date:  2009-02       Impact factor: 3.626

8.  CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail.

Authors:  Laura Rusconi; Lisa Salvatoni; Laura Giudici; Ilaria Bertani; Charlotte Kilstrup-Nielsen; Vania Broccoli; Nicoletta Landsberger
Journal:  J Biol Chem       Date:  2008-08-13       Impact factor: 5.157

9.  Biochemical analysis of histone deacetylase-independent transcriptional repression by MeCP2.

Authors:  Joshua W M Theisen; James S Gucwa; Timur Yusufzai; Mai T Khuong; James T Kadonaga
Journal:  J Biol Chem       Date:  2013-01-24       Impact factor: 5.157

10.  Absence of MeCP2 binding to non-methylated GT-rich sequences in vivo.

Authors:  John C Connelly; Justyna Cholewa-Waclaw; Shaun Webb; Verdiana Steccanella; Bartlomiej Waclaw; Adrian Bird
Journal:  Nucleic Acids Res       Date:  2020-04-17       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.